When Vomiting on Wegovy (semaglutide 2.4 mg) Becomes a Reason to Stop

How often does vomiting happen on Wegovy?

The label pools three placebo-controlled trials: 2,116 adults took semaglutide 2.4 mg weekly for up to 68 weeks and 1,261 took placebo. Vomiting occurred in 24% versus 6%, nausea in 44% versus 16%, diarrhea in 30% versus 16% and constipation in 24% versus 11%. Any gastrointestinal reaction occurred in 73% versus 47% [1].

Permanent discontinuation for an adverse reaction occurred in 6.8% versus 3.2%, and the three most common reasons were nausea (1.8% vs 0.2%), vomiting (1.2% vs 0%) and diarrhea (0.7% vs 0.1%) [1]. Vomiting is common; stopping because of it is not.

Severity is tracked separately. The label's severe gastrointestinal reaction warning, which covers nausea, vomiting and diarrhea together, applied to 4.1% of people on Wegovy injection versus 0.9% on placebo [1]. In STEP 1, the 68-week trial of 1,961 adults without diabetes, 4.5% of those on semaglutide stopped for a gastrointestinal event versus 0.8% on placebo [2].

Rates shift with the group studied. In the adolescent trial (ages 12 and older), vomiting occurred in 36% on semaglutide 2.4 mg and 10% on placebo [1]. With the 25 mg daily tablet, reaction types and frequencies were similar to the injection table, with severe GI reactions in 2% versus 0% and GI discontinuations in 3.4% versus 2% [1]. At 7.2 mg weekly, vomiting occurred in 22%, versus 16% at 2.4 mg and 6% on placebo [1].

What does the Wegovy label say to stop for?

For someone vomiting on Wegovy, the label's two stop instructions are for suspected pancreatitis and a suspected serious hypersensitivity reaction; a third warning concerns fluid loss.

Suspected pancreatitis. The label directs that Wegovy be discontinued and appropriate management started if pancreatitis is suspected. The symptoms it names are persistent or severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by nausea or vomiting [1]. Confirmed acute pancreatitis occurred in 4 Wegovy-treated adults (0.2 per 100 patient-years) and 1 adult on placebo [1].

A suspected serious hypersensitivity reaction. Anaphylaxis and angioedema have been reported with Wegovy, and the label says to discontinue Wegovy if a serious reaction is suspected and to promptly seek medical advice [1].

Vomiting that depletes volume. The label warns about acute kidney injury from volume depletion and directs monitoring of renal function in patients reporting reactions that could lead to volume depletion [1]. In the Wegovy program this occurred in 0.4 versus 0.2 cases per 100 patient-years (7 versus 4 adults), more often in people with existing kidney impairment and during dose titration, often after gastrointestinal fluid loss [1].

Severe gastrointestinal reactions. Wegovy is not recommended in patients with severe gastroparesis, and the label notes that use is associated with gastrointestinal reactions, sometimes severe [1]. Postmarketing reports in the label include ileus, intestinal obstruction and severe constipation with fecal impaction; frequency cannot be estimated from voluntary reports [1]. The label does not give a vomiting-based rule for stopping treatment.

What does the label say about dose steps and missed doses?

The label's schedule climbs every 4 weeks: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then maintenance from week 17 [1]. For weight reduction the recommended maintenance dose is 2.4 mg, with 1.7 mg as the other approved maintenance option; adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may go to a maximum of 7.2 mg weekly [1]. For a missed injection, the Wegovy label says the dose may be taken when the next scheduled dose is more than 2 days away, and after 2 or more consecutive missed doses the label says to re-escalate from a lower dose [1]. The drug stays in the body for about 5 to 7 weeks after the last 2.4 mg or 7.2 mg dose [1].

The clearest dose comparison in the label comes from the 7.2 mg program: vomiting in 22% on 7.2 mg, 16% on 2.4 mg and 6% on placebo, with gastrointestinal discontinuations of 3%, 3% and 0.3% [1]. Tripling the weekly dose added six percentage points of vomiting without changing the share who stopped for gastrointestinal reasons [1].

What happens to weight if Wegovy is stopped?

In STEP 4, 803 adults who had lost a mean 10.6% of body weight during a 20-week run-in were randomized to continue semaglutide 2.4 mg or switch to placebo for 48 weeks. Between week 20 and week 68, those who continued lost a further 7.9% while those switched to placebo gained 6.9% [3]. In an extension of STEP 1 with 327 participants, those who had taken semaglutide had lost an average of 17.3% at week 68 and regained 11.6 percentage points in the year after treatment stopped, leaving a net loss of 5.6% from baseline [4].